Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil)
SARS-Brazil
Brazilian COVID-19 Registry for Clinical Presentation of Individuals With COVID-19: a National, Multicentre, Prospective Observational Study (SARS-Brazil)
1 other identifier
observational
1,587
1 country
14
Brief Summary
This is a registry-based cohort study of all adult patients (≥18 years) with confirmed or suspected SARS-CoV-2 infection. The main goal is to describe mortality incidence, demographic characteristics, coexisting conditions, treatments, outcomes among SARS-CoV2 infected patients. A secondary goal is to identify biological factors (OMICS - genomic, proteomic and metabolomics characterization) associated with severity conditions for these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2020
Typical duration for all trials
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 13, 2020
CompletedFirst Posted
Study publicly available on registry
July 21, 2020
CompletedStudy Start
First participant enrolled
July 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2022
CompletedMarch 9, 2023
December 1, 2022
8 months
July 13, 2020
March 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All-cause mortality
All-cause mortality rates at 60 days
60 Days
Secondary Outcomes (5)
Incidence and course of symptoms of COVID-19 infection
60 Days
Hospitalizations
60 Days
Oxygen supplementation
60 Days
Use of invasive mechanical ventilation
60 Days
Intensive care unit length of stay
60 Days
Other Outcomes (3)
Serum proteomic
60 Days
Serum metabolomic
60 Days
Genomic description
60 Days
Study Arms (2)
Hospitalized patients
Patient who are suspected or confirmed SARS-CoV2 infection need hospitalization.
Non-hospitalized patients
Patient who are suspected or confirmed SARS-CoV2 infection non-hospitalized.
Interventions
Eligibility Criteria
SARS-Brazil Registry is designed as multicenter observational cohort of adult patients (≥18 years old), that are confirmed or suspected SARS-CoV-2 infection in Brazilian hospitals.
You may qualify if:
- Adult patients (≥18 years);
- Confirmed or suspected SARS-CoV2 infection
You may not qualify if:
- Patient who expressed opposition to participation in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hospital Israelita Albert Einsteinlead
- Ministry of Health, Brazilcollaborator
Study Sites (14)
Hospital de Emergencia Dr. Daniel Houly
Arapiraca, Alagoas, Brazil
Alencar Serviços Médicos Ltda
Barbalha, Ceará, Brazil
Hospital Estadual Jayme dos Santos Neves
Serra, Espírito Santo, Brazil
Hospital Santa Rita de Cássia
Vitória, Espírito Santo, Brazil
Universidade Federal da Bahia
Vitória da Conquista, Estado de Bahia, Brazil
Fundação Educacional Lucas Machado
Belo Horizonte, Minas Gerais, Brazil
Fundação Hopitalar São Francisco de Assis
Belo Horizonte, Minas Gerais, Brazil
Hospital Santa Lucia
Poços de Caldas, Minas Gerais, Brazil
Hospital Giselda Trigueiro
Natal, Rio Grande do Norte, Brazil
Hospital São Vicente de Paulo
Passo Fundo, Rio Grande do Sul, Brazil
Santa Casa de Votuporanga
Votuporanga, São Paulo, Brazil
Hospital Municipal Vila Santa Catarina
São Paulo, Brazil
Hospital São Camilo - Ipiranga
São Paulo, Brazil
Hospital São Camilo - Pompéia
São Paulo, Brazil
Related Publications (1)
Fonseca HAR, Pereira AJ, Nawa RK, Sant'Anna VAR, Almeida TF, Guimaraes HP, Tognon AP, Marques LM, Silva LSCD, Bittencourt RS, Gomes CP, Martins PA, Oliveira AL, Milan EP, Dall'Orto FTC, Hoffman Filho CR, Almeida G, Hohmann FB, Moia DDF, Piano LPA, Machado FP, Soares RVP, Damiani LP, Assis SRL, Amaro Junior E, Rizzo LV, Berwanger O. Mortality, hospitalizations, and persistence of symptoms in the outpatient setting of the first COVID-19 wave in Brazil: results of SARS-Brazil cohort study. Einstein (Sao Paulo). 2024 Aug 9;22:eAO0652. doi: 10.31744/einstein_journal/2024AO0652. eCollection 2024.
PMID: 39140573DERIVED
Biospecimen
Blood, serum, plasma and nasal swab
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Otávio Berwanger, PhD
Hospital Israelita Albert Einstein
- PRINCIPAL INVESTIGATOR
Henrique A Fonseca, PhD
Hospital Israelita Albert Einstein
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 13, 2020
First Posted
July 21, 2020
Study Start
July 27, 2020
Primary Completion
March 30, 2021
Study Completion
December 30, 2022
Last Updated
March 9, 2023
Record last verified: 2022-12